The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.
If you are not happy with the results below please do another search
50 search results for:
The U.S. Centers for Disease Control and Prevention said on November 29 everyone aged 18 years and older should get a booster shot, as the CDC looks to tackle a new and highly infectious strain of the coronavirus that is quickly spreading across the globe.
Reinfections with the virus that causes COVID-19 are rarely severe, new findings suggest. Additionally, researchers say in COVID-19 survivors struggling with lingering shortness of breath for which doctors do not have an explanation, cardiac stress testing may help identify the cause of the problem.
BioNTech, Moderna and Johnson & Johnson are working on vaccines that specifically target Omicron in case their existing shots are not effective against the new coronavirus variant, the companies said on November 29.
The New York Times profiled the success story of a type 1 diabetes patient who was dosed with Vertex Pharmaceuticals’ experimental fully differentiated pancreatic islet cell replacement therapy, and after an infusion of VX-880, he began to produce his own insulin.
Pfizer Inc. now expects to manufacture 80 million treatment courses of the company’s experimental COVID-19 antiviral drug, up from a previous forecast of 50 million, Chief Executive Officer Albert Bourla said in a CNBC interview on November 29.
The latest data from Merck and Ridgeback Biotherapeutics’ MOVe-OUT trial on the use of molnupiravir to treat COVID-19 in adults has shown a lower efficacy than previously reported.
During Thanksgiving weekend, America – and the world – learned a new word: Omicron. It is the 15th letter of the Greek alphabet and has a numerical value of 70. In the current context, however, where Greek numbers identify variants of the SARS-CoV-2 virus, omicron has a value of 30 – 30 gene mutations in its spike protein.
BioNTech SE said on Monday the company had started work on a vaccine tailored to Omicron, the worrying new coronavirus variant detected in South Africa.
Krystal Biotech, a biopharmaceutical firm that creates gene-based therapies for rare diseases, announced positive topline results from an ongoing Phase III trial on a potential treatment for dystrophic epidermolysis bullosa (dystrophic EB).